Release Summary

Seres Therapeutics, Inc. (NASDAQ:MCRB) announced the initiation of a Phase 3 SER-109 clinical study (ECOSPOR III) in patients with multiply recurrent C. difficile infection.

Seres Therapeutics, Inc.